Aadi Bioscience, Inc. (AADI)
NASDAQ: AADI · Real-Time Price · USD
2.390
+0.030 (1.27%)
Dec 3, 2024, 1:59 PM EST - Market open
Aadi Bioscience Revenue
Aadi Bioscience had revenue of $7.21M in the quarter ending September 30, 2024, with 21.03% growth. This brings the company's revenue in the last twelve months to $25.07M, up 7.80% year-over-year. In the year 2023, Aadi Bioscience had annual revenue of $24.35M with 60.06% growth.
Revenue (ttm)
$25.07M
Revenue Growth
+7.80%
P/S Ratio
2.54
Revenue / Employee
$281,685
Employees
89
Market Cap
58.91M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 24.35M | 9.14M | 60.06% |
Dec 31, 2022 | 15.22M | 14.10M | 1,258.57% |
Dec 31, 2021 | 1.12M | -13.46M | -92.32% |
Dec 31, 2020 | 14.58M | 13.83M | 1,846.60% |
Dec 31, 2019 | 749.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAADI News
- 27 days ago - Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update - PRNewsWire
- 4 weeks ago - Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update - PRNewsWire
- 3 months ago - Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates - PRNewsWire
- 4 months ago - Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update - PRNewsWire
- 4 months ago - Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update - PRNewsWire
- 6 months ago - Aadi Bioscience to Participate in the Jefferies Healthcare Conference - PRNewsWire
- 6 months ago - Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting - PRNewsWire